[1] Zhao Y, Sun DL, Bouchard HC, et al. Coronavirus disease 2019 versus influenza a in children: an observational control study in China. Biomed Environ Sci, 2020; 33, 614−9.
[2] Wang N, Yang MB, Yang PY, et al. A case series of olfactory dysfunction in imported COVID-19 patients: a 12-month follow-up study. Biomed Environ Sci, 2022; 35, 402−11.
[3] Ma Y, Mishra SR, Han XK, et al. The relationship between time to a high COVID-19 response level and timing of peak daily incidence: an analysis of governments' Stringency Index from 148 countries. Infect Dis Poverty, 2021; 10, 96. doi:  10.1186/s40249-021-00880-x
[4] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Wkly, 2020; 2, 113−22. doi:  10.46234/ccdcw2020.032
[5] Zeng N, Zhao YM, Yan W, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry, 2022.
[6] Han Q, Zheng B, Daines L, et al. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens, 2022; 11, 269. doi:  10.3390/pathogens11020269
[7] Wang YD, Xu J, Wang Y, et al. Prevalence of comorbid tuberculosis amongst COVID-19 patients: a rapid review and meta-analysis. Int J Clin Pract, 2021; 75, e14867.
[8] Gao Y, Liu M, Chen YM, et al. Association between tuberculosis and COVID-19 severity and mortality: a rapid systematic review and meta-analysis. J Med Virol, 2021; 93, 194−6. doi:  10.1002/jmv.26311
[9] Tadolini M, García-García JM, Blanc FX, et al. On tuberculosis and COVID-19 co-infection. Eur Respir J, 2020; 56, 2002328. doi:  10.1183/13993003.02328-2020
[10] Visca D, Ong CWM, Tiberi S, et al. Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. Pulmonology, 2021; 27, 151−65. doi:  10.1016/j.pulmoe.2020.12.012
[11] Aggarwal AN, Agarwal R, Dhooria S, et al. Active pulmonary tuberculosis and coronavirus disease 2019: a systematic review and meta-analysis. PLoS One, 2021; 16, e0259006. doi:  10.1371/journal.pone.0259006
[12] The Central People’s Government of the People's Republic of China. Notice of the state council’s joint prevention and control mechanism for novel coronavirus infected pneumonia on printing and distributing the regulations on the management of asymptomatic infections of the novel coronavirus. http://www.gov.cn/zhengce/content/2020-04/08/content_5500371.htm?trs=1. [2022-08-05]. (In Chinese)
[13] National Health and Family Planning Commission of the P.R.C. Diagnosis for pulmonary tuberculosis (WS 288—2017). Chinese Published. 2017. (In Chinese)
[14] Ministry of Health Bureau of Disease Control and Prevention, Ministry of Health Department of Medical Administration, Chinese Center for Disease Control and Prevention. China tuberculosis program implementation guide (2008 Edition). Peking Union Medical College Press. 2009. (In Chinese)
[15] Stavem K, Ghanima W, Olsen MK, et al. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax, 2021; 76, 405−7. doi:  10.1136/thoraxjnl-2020-216377
[16] Mandal S, Barnett J, Brill SE, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax, 2021; 76, 396−8. doi:  10.1136/thoraxjnl-2020-215818
[17] Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA, 2020; 324, 603−5. doi:  10.1001/jama.2020.12603
[18] Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020; 5, 1265−73. doi:  10.1001/jamacardio.2020.3557
[19] D’Cruz RF, Waller MD, Perrin F, et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Res, 2021; 7, 00655−2020.
[20] Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep, 2021; 11, 16144. doi:  10.1038/s41598-021-95565-8
[21] Fumagalli C, Zocchi C, Tassetti L, et al. COVID-19 Follow-up study Group. Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study. Eur J Intern Med, 2022; 97, 36−41. doi:  10.1016/j.ejim.2021.11.018
[22] Huang LX, Yao Q, Gu XY, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet, 2021; 398, 747−58. doi:  10.1016/S0140-6736(21)01755-4
[23] Yang XY, Hou C, Shen Y, et al. Two-year health outcomes in hospitalized COVID-19 survivors in China. JAMA Netw Open, 2022; 5, e2231790. doi:  10.1001/jamanetworkopen.2022.31790
[24] Dao TL, Hoang VT, Gautret P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis, 2021; 40, 13−25. doi:  10.1007/s10096-020-04088-z
[25] Hoang T. Characteristics of COVID-19 recurrence: a systematic review and meta-analysis. Ann Glob Health, 2021; 87, 28. doi:  10.5334/aogh.3163
[26] Mirsaeidi M, Sadikot RT. Patients at high risk of tuberculosis recurrence. Int J Mycobacteriol, 2018; 7, 1−6. doi:  10.4103/ijmy.ijmy_164_17
[27] Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med, 2005; 171, 1430−5. doi:  10.1164/rccm.200409-1200OC
[28] Ruan QL, Yang QL, Sun F, et al. Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China. Clin Microbiol Infect, 2022; 28, 684−9. doi:  10.1016/j.cmi.2021.09.022
[29] He GQ, Wu J, Shi JC, et al. COVID-19 in tuberculosis patients: a report of three cases. J Med Virol, 2020; 92, 1802−6. doi:  10.1002/jmv.25943
[30] Ji Y, Cao HF, Liu Q, et al. Screening for pulmonary tuberculosis in high-risk groups of diabetic patients. Int J Infect Dis, 2020; 93, 84−9. doi:  10.1016/j.ijid.2020.01.019
[31] Qin F, Barry PM, Pascopella L. Factors associated with extended treatment among tuberculosis patients at risk of relapse in California. Int J Tuberc Lung Dis, 2016; 20, 363−9. doi:  10.5588/ijtld.15.0469
[32] Du J, Zhang L, Ma Y, et al. Treatment and recurrence on re-treatment tuberculosis patients: a randomized clinical trial and 7-year perspective cohort study in China. Eur J Clin Microbiol Infect Dis, 2020; 39, 93−101. doi:  10.1007/s10096-019-03696-8
[33] Sarma U, Mishra V, Goel J, et al. COVID-19 pneumonia with delayed viral clearance in a patient with active drug-resistant pulmonary tuberculosis. Ind J Crit Care Med, 2020; 24, 1132−4. doi:  10.5005/jp-journals-10071-23662
[34] Noori MAM, Younes I, Latif A, et al. Reactivation of tuberculosis in the setting of COVID-19 infection. Cureus, 2022; 14, e23417.
[35] Small CL, Shaler CR, McCormick S, et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol, 2010; 184, 2048−56. doi:  10.4049/jimmunol.0902772
[36] Yang H, Lu SH. COVID-19 and tuberculosis. J Transl Int Med, 2020; 8, 59−65. doi:  10.2478/jtim-2020-0010